Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palonosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 10/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palonosetron SCHEMBL29402278 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL4058558 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL2989775 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7782594 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7277880 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL10066801 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3748 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL13240607 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3747 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3746 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| CN-119894893-A | Sulfone substituted pyrido [3,4-D ] pyrimidine derivatives for the treatment of cancer | 拜耳公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | claimed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | claimed |
| WO-2024188937-A1 | COMBINATIONS OF ATR KINASE INHIBITORS AND PARP INHIBITORS TO TREAT HYPER-PROLIFERATIVE CONDITIONS E.G. CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-19 | — | — | WO | claimed |
| US-20240261289-A1 | SOTORASIB DOSING REGIMEN | AMGEN INC. | 2024-08-08 | — | — | US | claimed |
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | US | claimed |
| WO-2022261025-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF SOTORASIB AND TRAMETINIB | AMGEN INC. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022245857-A1 | SOTORASIB DOSING REGIMEN | AMGEN INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022219035-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-20 | — | — | WO | claimed |
| EP-4074317-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | Bayer AG (DE) | 2022-10-19 | — | — | EP | claimed |
| WO-2022197865-A1 | SOTORASIB DOSING REGIMEN | AMGEN INC. (US) | 2022-09-22 | — | — | WO | claimed |
| EP-4038054-A1 | PYRIMIDINEDIONE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-08-10 | — | — | EP | claimed |
| EP-1940366-B9 | SOFT CAPSULES COMPRISING PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY | HELSINN HEALTHCARE SA (CH) | 2009-12-02 | — | — | EP | claimed |
| EP-1940366-B1 | SOFT CAPSULES COMPRISING PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY | HELSINN HEALTHCARE SA (CH) | 2009-04-08 | — | — | EP | claimed |
| US-5202333-A | Tricyclic 5-HT3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 1993-04-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | HTR3A 4461/4885HTR3B 4585/4885ADRA2A 2381/4885 |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | HTR3A 4766/4885HTR3B 4785/4885ADRA2A 4085/4885 |
| US-20240261289-A1 | SOTORASIB DOSING REGIMEN | KRAS, NRAS, HRAS | HTR3A 4405/4885HTR3B 4397/4885ADRA2A 4393/4885 |
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | DPYD, TYMP, TYMS | HTR3A 2877/4885HTR3B 3193/4885ADRA2A 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.